NewzenPharma

NewzenPharma is a U.S.-based, manufacturing-driven biotechnology and pharmaceutical company focused primarily on oncology, with an emphasis on therapies that target DNA repair mechanisms in cancer cells. The company presents itself as a clinical-stage biotech while also marketing a portfolio of generic and consumer-style pharmaceutical products through its website. Its named oncology pipeline includes Newzen-138 for prostate cancer, Newzen-150 as an antibody-based cancer therapy, and Newzen-170 as a cell therapy program. NewzenPharma highlights in-house R&D, formulation, analytical development, regulatory capabilities, and manufacturing ambitions, and says it has commercial reach across the U.S., Asia, Africa, and the EU. Publicly available information is limited and several claims on its website are not independently well substantiated, so some pipeline and stage details should be treated cautiously.